Table 4. Death receptors and their ligands.
| gene | log2 FC (NC/CR) | p | q | avg. signal |
|---|---|---|---|---|
| tumor necrosis factor α (TNF) | -0.06 | 0.64 | 0.86 | 177 |
| tumor necrosis factor α, natural antisense transcript (TNF-AS1) | -0.66 | <0.01 | 0.07 | 89 |
| TNF receptor superfamily, member 1A (TNFRSF1A), TNFR1 | +0.24 | 0.05 | 0.27 | 1406 |
| TNF receptor superfamily, member 1B (TNFRSF1B), TNFR2 | -0.33 | 0.06 | 0.29 | 1940 |
| TNF receptor-associated factor 1 (TRAF1) | -0.37 | <0.01 | 0.06 | 1168 |
| TNF receptor-associated factor 2 (TRAF2) | -0.05 | 0.52 | 0.79 | 2218 |
| baculoviral IAP repeat-containing 3, cIAP2 (BIRC3) | -0.81 | <0.01 | 0.05 | 538 |
| BCL2-related protein A1 (BCL2A1) | -1.18 | 0.01 | 0.09 | 825 |
| amyloid beta (A4) precursor protein (APP) | +0.55 | 0.01 | 0.12 | 2978 |
| beta-site APP-cleaving enzyme 1, beta-secretase (BACE1) | +0.34 | 0.01 | 0.09 | 121 |
| beta-site APP-cleaving enzyme 2, theta-secretase (BACE2) | +0.64 | 0.03 | 0.19 | 1239 |
| TNF receptor superfamily, member 21, DR6 (TNFRSF21) | +0.59 | <0.01 | 0.03 | 4991 |
Negative log2 FC values indicate higher expression in tissues from persistently infected FMDV carriers (CR) compared to non-carriers (NC). All p- and q-values that met the established significance criteria are marked in bold. (p: unadjusted p-value at gene level, q: transcriptome-wide p-value after Benjamini-Hochberg adjustment, avg. signal: average intensity of this probe across all arrays)